A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

With drug rebates on the chopping block, stakeholders should prepare for change

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Early this year, the US Department of Health and Human Services (HHS) proposed eliminating safe-harbor protections for the rebates drug manufacturers pay to pharmacy benefit managers (PBMs), Medicare Part D plans, and Medicaid managed care organizations. At the same time, HHS proposed two new safe-harbor protections for some point-of-sale (POS) price reductions on prescription drugs and certain PBM service fees.

Read more

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more

FDA workshop on achieving medical device safety and cybersecurity: Why trustworthiness, transparency, and resilience are critical

by Steven Darroch, Senior Manager, and Nick Sikorski, Manager, Deloitte & Touche LLP, Deloitte & Touche LLP

An ever-expanding list of medical devices are able to generate, collect, analyze, and transmit data, creating the Internet of Medical Things (IoMT)—a connected infrastructure of health systems and services. As connected devices have become more common, the ability to protect digital information has become essential. Manufacturers that have a solid risk-management strategy could gain a competitive advantage.

Read more

As interest in oncology grows, real-world data could help biopharma firms improve clinical research, reduce costs

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

Early this year, I attended the annual J.P. Morgan Healthcare conference where investors and biopharmaceutical company executives were excited about the growth of personalized therapies—particularly in oncology. This optimism was somewhat tempered by some of the many challenges in oncology research and development (R&D) and bringing high-cost therapies to market. However, advances in digital health,

Read more

Empowered patients, value, and digital are driving us to a new health model

by Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP

Five years ago—recognizing that the shift to value-based, personalized health care would have a profound and transformational impact on the industry—we launched ConvergeHEALTH. Our goal was to team up with leading health care institutions, technology companies, life sciences innovators, and patient advocacy groups to create new platforms and solutions to support this transformation for the benefit of patients.

Read more

Emerging trends in life sciences indicate cautious optimism for M&A in 2019

by Susan Dettmar, principal, US M&A consultative services leader, and Kushan Biswas, Life Sciences M&A senior manager, Deloitte Consulting LLP

Each year during the second week of January, health care executives from around the globe descend on San Francisco to discuss ground-breaking innovations, investment opportunities, and potential disruptive plays across the life sciences sector. During this year’s J.P. Morgan Healthcare Conference, we hosted a number of sessions with clients. A few topics—continued investment in oncology and gene therapies,

Read more